Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions?

Van Boerdonk,Robert  A.A.; Brokx,Hes  A.P.; Lee,Pyng; Kooi,Clarissa; Postmus,Pieter  E.; Snijders,Peter  J.F.; Grünberg,Katrien; Thunnissen,Erik; Sutedja,Thomas  G.; Daniels,Johannes  M.A.; Heideman,Daniëlle  A.M.

doi:10.3892/ol.2013.1262

Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions?

Authors:
- Robert A.A. Van Boerdonk
- Hes A.P. Brokx
- Pyng Lee
- Clarissa Kooi
- Pieter E. Postmus
- Peter J.F. Snijders
- Katrien Grünberg
- Erik Thunnissen
- Thomas G. Sutedja
- Johannes M.A. Daniels
- Daniëlle A.M. Heideman
View Affiliations

Affiliations: Department of Pathology, VU University Medical Center, Amsterdam 1007 MB, The Netherlands, Department of Pulmonary Diseases, VU University Medical Center, Amsterdam 1007 MB, The Netherlands, Department of Medicine, National University Hospital, Singapore 119228, Republic of Singapore
Published online on: March 19, 2013 https://doi.org/10.3892/ol.2013.1262
Pages: 1591-1594

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increased concentrations of free-circulating plasma DNA (cpDNA) are observed in patients with invasive cancer, including lung cancer. Whether cpDNA levels are elevated in subjects with high-grade pre-invasive lesions of lung squamous cell carcinoma (SqCC) and whether its detection may be of value for identifying subjects at the highest risk of developing lung SqCC is currently unknown. The present study assessed cpDNA levels in subjects with high- and low‑grade pre-invasive squamous endobronchial lesions relative to patients with clinically overt lung SqCC and healthy controls using real-time quantitative PCR methodology. The median cpDNA levels of the patients with invasive lung SqCC (n=16) were significantly higher compared with those of the healthy controls (n=16; P<0.01), whereas the cpDNA levels in the subjects with pre-invasive lesions (n=20) did not differ from those of the controls (P=0.29). The cpDNA levels in subjects with high-grade pre-invasive lesions were highly similar to those diagnosed with low-grade pre-invasive lesions (P=0.85). Our data suggest that cpDNA levels are not increased during the pre-invasive stages of lung squamous carcinogenesis.

View Figures

View References

1	National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, Ascher S, Bailey W, Brewer B, Church T, Engelhard D, Ford M, Fouad M, Freedman M, Gelmann E, Gierada D, Hocking W, Inampudi S, Irons B, Johnson CC, Jones A, Kucera G, Kvale P, Lappe K, Manor W, Moore A, Nath H, Neff S, Oken M, Plunkett M, Price H, Reding D, Riley T, Schwartz M, Spizarny D, Yoffie R and Zylak C; Lung Screening Study Research Group: Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer. 47:9–15. 2005. View Article : Google Scholar : PubMed/NCBI
3	Henschke CI, Naidich DP, Yankelevitz DF, McGuinness G, McCauley DI, Smith JP, Libby D, Pasmantier M, Vazquez M, Koizumi J, Flieder D, Altorki N and Miettinen OS: Early lung cancer action project: initial findings on repeat screenings. Cancer. 92:153–159. 2001. View Article : Google Scholar : PubMed/NCBI
4	McWilliams A, Mayo J, MacDonald S, LeRiche JC, Palcic B, Szabo E and Lam S: Lung cancer screening: a different paradigm. Am J Respir Crit Care Med. 168:1167–1173. 2003. View Article : Google Scholar : PubMed/NCBI
5	Goulart BH, Bensink ME, Mummy DG and Ramsey SD: Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw. 10:267–275. 2012.PubMed/NCBI
6	Chen W, Gao X, Tian Q and Chen L: A comparison of autofluorescence bronchoscopy and white light bronchoscopy in detection of lung cancer and preneoplastic lesions: a meta-analysis. Lung Cancer. 73:183–188. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bota S, Auliac JB, Paris C, Métayer J, Sesboüé R, Nouvet G and Thiberville L: Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med. 164:1688–1693. 2001. View Article : Google Scholar : PubMed/NCBI
8	Lam S, Kennedy T, Unger M, Miller YE, Gelmont D, Rusch V, Gipe B, Howard D, LeRiche JC, Coldman A and Gazdar AF: Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest. 113:696–702. 1998. View Article : Google Scholar : PubMed/NCBI
9	Lam S and Palcic B: Re: Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst. 91:561–562. 1999. View Article : Google Scholar
10	Loewen G, Natarajan N, Tan D, Nava E, Klippenstein D, Mahoney M, Cummings M and Reid M: Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax. 62:335–340. 2007. View Article : Google Scholar : PubMed/NCBI
11	Fleischhacker M and Schmidt B: Free circulating nucleic acids in plasma and serum (CNAPS) - Useful for the detection of lung cancer patients? Cancer Biomark. 6:211–219. 2010.PubMed/NCBI
12	Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D, Carbonelli C, De Franco S, Brini M, Sgarbi G and Lodi R: Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 64:92–97. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA and Tavecchio L: Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61:4675–4678. 2001.PubMed/NCBI
14	Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA and Pastorino U: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 21:3902–3908. 2003. View Article : Google Scholar : PubMed/NCBI
15	Szpechcinski A, Dancewicz M, Kopinski P, Kowalewski J and Chorostowska-Wynimko J: Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls. Eur J Med Res. 14(Suppl 4): 237–240. 2009. View Article : Google Scholar : PubMed/NCBI
16	van Boerdonk RA, Sutedja TG, Snijders PJ, Reinen E, Wilting SM, van de Wiel MA, Thunnissen FE, Duin S, Kooi C, Ylstra B, Meijer CJ, Meijer GA, Grünberg K, Daniels JM, Postmus PE, Smit EF and Heideman DA: DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. Am J Respir Crit Care Med. 184:948–956. 2011.PubMed/NCBI
17	Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 6th edition. Wiley-Liss; New York, NY: 2002
18	Travis WD, Brambilla E, Muller-Hermelink KM and Harris CC: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: 2004
19	de Wilde J, De-Castro AJ, Snijders PJ, Meijer CJ, Rösl F and Steenbergen RD: Alterations in AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. Cell Oncol. 30:77–87. 2008.PubMed/NCBI
20	Hesselink AT, van den Brule AJ, Groothuismink ZM, Molano M, Berkhof J, Meijer CJ and Snijders PJ: Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol. 43:4868–4871. 2005. View Article : Google Scholar : PubMed/NCBI
21	Roz L, Verri C, Conte D, Miceli R, Mariani L, Calabro’ E, Andriani F, Pastorino U and Sozzi G: Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: a validation analysis. Lung Cancer. 66:270–271. 2009. View Article : Google Scholar : PubMed/NCBI
22	Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Lo Vollo S, Verri C and Pastorino U: Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med. 179:69–74. 2009.PubMed/NCBI
23	Shukla D, Kale AD, Hallikerimath S, Yerramalla V and Subbiah V: Can quantifying free-circulating DNA be a diagnostic and prognostic marker in oral epithelial dysplasia and oral squamous cell carcinoma? J Oral Maxillofac Surg. Jun 29–2012, (Epub ahead of print).
24	Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Kobayashi N, Hayashi S, Hosomi T, Hirai M, Sueoka E and Kimura S: Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol. 7:1369–1381. 2012. View Article : Google Scholar : PubMed/NCBI
25	Breuer RH, Pasic A, Smit EF, van Vliet E, Vonk Noordegraaf A, Risse EJ, Postmus PE and Sutedja TG: The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res. 11(2 Pt 1): 537–543. 2005.PubMed/NCBI